Royalty Pharma PLC (NASDAQ:RPRX) Plans Dividend Increase – $0.24 Per Share

Royalty Pharma PLC (NASDAQ:RPRX) declared a quarterly dividend on Friday, January 9th. Stockholders of record on Friday, February 20th will be paid a dividend of 0.235 per share by the biopharmaceutical company on Tuesday, March 10th. This represents a c) annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Friday, February 20th. This is a 6.8% increase from Royalty Pharma’s previous quarterly dividend of $0.22.

Royalty Pharma has a payout ratio of 17.5% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Royalty Pharma to earn $4.86 per share next year, which means the company should continue to be able to cover its $0.88 annual dividend with an expected future payout ratio of 18.1%.

Royalty Pharma Stock Down 0.2%

RPRX stock traded down $0.09 on Friday, reaching $40.17. 2,397,981 shares of the company traded hands, compared to its average volume of 3,863,313. The company has a market cap of $23.19 billion, a P/E ratio of 30.43, a price-to-earnings-growth ratio of 1.98 and a beta of 0.43. Royalty Pharma has a one year low of $27.47 and a one year high of $41.70. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48. The firm has a fifty day simple moving average of $39.13 and a 200-day simple moving average of $37.24.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.06. The company had revenue of $609.29 million for the quarter, compared to the consensus estimate of $765.01 million. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%. Research analysts anticipate that Royalty Pharma will post 4.49 earnings per share for the current year.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.